悅康藥業(688658.SH):子公司YKYY029注射液獲得FDA臨牀試驗批準
格隆匯7月23日丨悅康藥業(688658.SH)公佈,子公司北京悅康科創醫藥科技股份有限公司(簡稱“悅康科創”)於近日獲得美國食品藥品監督管理局(簡稱“FDA”)關於同意YKYY029注射液用於治療高血壓進行臨牀試驗的函告(StudyMayProceedLetter,IND編號:176571)。YKYY029注射液是悅康科創和公司全資子公司杭州天龍藥業有限公司自主開發的靶向AGT基因的小幹擾核糖核酸(siRNA)藥物,具有全新的序列,並採用了公司自主研發的siRNA序列全新修飾模板和GalNAc遞送系統,公司享有全球獨佔權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.